275 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Pacific Wealth Strategies Group Inc.

Pacific Wealth Strategies Group Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, Holdings Channel.com reports. The fund bought 275 shares of the company’s stock, valued at approximately $214,000.

A number of other large investors have also recently made changes to their positions in LLY. Penserra Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 18.4% in the third quarter. Penserra Capital Management LLC now owns 6,056 shares of the company’s stock valued at $3,251,000 after acquiring an additional 940 shares during the period. Advisors Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 4.6% during the third quarter. Advisors Capital Management LLC now owns 5,312 shares of the company’s stock worth $2,854,000 after purchasing an additional 235 shares during the period. Creative Planning lifted its holdings in shares of Eli Lilly and Company by 8.0% during the third quarter. Creative Planning now owns 161,849 shares of the company’s stock worth $86,934,000 after purchasing an additional 12,011 shares during the period. Resources Management Corp CT ADV lifted its holdings in shares of Eli Lilly and Company by 15.1% during the third quarter. Resources Management Corp CT ADV now owns 1,336 shares of the company’s stock worth $718,000 after purchasing an additional 175 shares during the period. Finally, Spartan Planning & Wealth Management acquired a new stake in shares of Eli Lilly and Company during the third quarter worth $395,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock traded up $7.90 during trading on Tuesday, hitting $925.90. The stock had a trading volume of 1,285,353 shares, compared to its average volume of 2,930,049. The company’s 50 day moving average price is $835.30 and its two-hundred day moving average price is $754.97. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $930.00. The stock has a market cap of $879.98 billion, a price-to-earnings ratio of 136.28, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.62 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

Several brokerages recently weighed in on LLY. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Bank of America reiterated a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a research report on Monday, June 24th. Argus increased their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,001.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Finally, Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $816.78.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Insiders sold 911,111 shares of company stock worth $783,500,842 in the last 90 days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.